Inscinstech Co., Ltd. is an innovative high-tech enterprise focusing on biological separation technology. It has a large number of patents and computer software copyrights. The company has established marketing and service centers in Suzhou, China. It is committed to providing global customers with high-quality biological separation equipment and chemical analysis instruments, reducing customer operating costs and creating value for customers. The company has established R & D centers , which run by an international level technical R & D team with a perfect product R & D system. The technical team of the company has more than ten years of R & D, engineering and industrialization experience in the fields of laboratory sample pretreatment, chromatography, spectrum and mass spectrometry analysis instruments, automation equipment and machine vision technology, and provides customers with all-round intelligent solutions from sample separation, pretreatment to laboratory chemical analysis.
innoME GmbH
Your All-In-One Cell Culture Partner. We strive to serve your needs and applictaions in the lab with our products and services. From high-qualtity standard consumables to individual OEM development. From tailored reagents, sera and other media to novelties in cell culture monitoring. We solve problems complete around injecting molding for life science. We produce OEM products for different biotechnology and pharmaceutical customers. Products are: – Well plates – Impedance plates – Microfluidic chips and much more
Indian Immunologicals Ltd
Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player, conceptualizing and executing the products journey from bench at the R&D lab to its sale at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in these two segments, we recognized both, the inter-dependence, and inter-linkages of the two segments and as a result have been spearheading the One Health initiative since a long time. IIL had its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturer of the country and the region. We ventured into manufacturing human vaccines by 1998 on specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of nine new vaccine candidates. We have a huge pipeline of vaccine for Animal Health segment. We are one of the leading manufacturers of Pet Vaccines. IIL has four world class manufacturing facilities spread across India and New Zealand. IIL collaborates with several leading pharma/vaccines companies within India and outside for manufacturing and research collaborations. Our capabilities and experience in handling projects across varied platforms technologies, across varied scales (small to very high) enable us to offer both flexibility and confidence to our partners for a smooth execution. We solicit cooperation proposals to build synergistic relationships. | Indian Immunologicals Limited (IIL) is a leading vaccine manufacturer. We are a fully integrated player that conceptualizes and executes the products journey from bench at the R&D lab to its use at the clinic. Our journey of forty years of saving lives through developing, scaling up and executing huge scale manufacturing projects has honed our skills of projects management, efficient execution, excellence in regulatory compliance and at the same time offering agility, competitiveness, and trusted result-oriented approach. IIL has a strong portfolio of products, both in the human health segment and animal health segment. We have been spearheading the One Health initiative, globally. As a result of our presence in the two segments, we recognized both, the interdependence, and interlinkages of the two segments and as a result have been spearheading the One Health initiative for a long time. IIL has its humble beginnings as a veterinary vaccine manufacturing company in the year 1982. Since then, it has scaled up to become one of the major vaccines manufacturers of the region. After starting off an animal vaccine manufacturer, we started manufacturing human vaccines in 1998 on a specific request by the Government of India. As a result, IIL became the second company in the world and first in India to launch purified vero cell rabies vaccine (PVRV) and markets it under the brand – Abhayrab. It is today by far the largest manufacturer of human rabies vaccine in the world. IIL today has a portfolio of eight commercial human vaccines and has a pipeline of five new vaccine candidates. We are currently serving and touching lives in more than fifty (60) countries by exporting both our animal health and human health products. We have four world class manufacturing units spear across India and New Zealand. IIL, through its state-of-the-art facilities, collaborates with several leading pharma/vaccines companies within India and outside.
Immunology Consultants Laboratory, Inc.
ICL is a U.S.-based manufacturer of biochemical reagents and life science products, specializing in the production of antibodies and ELISA kits for both IVD and research applications. With over 45 years in the biotech industry, ICL has built a strong presence among the world’s leading research institutions, in vitro diagnostics (IVD) manufacturers, and biopharma companies. Backed by in-house research and development, ICL also offers custom solutions for research teams and IVD companies with needs that go beyond standard offerings. | With over 45 years of expertise, ICL is a U.S.-based manufacturer of high-quality antibodies and immunoassays serving the global life science market, including CDMOs, pharmaceutical companies, and IVD manufacturers. From our laboratory in Portland, Oregon, we produce reliable primary and secondary antibodies, ELISA kits, and host cell protein (HCP) detection assays in both human and animal models. Whether you’re developing a commercial diagnostic, optimizing a bioprocess, or conducting critical research, our reagents are designed to meet your performance standards. Explore our catalog or contact us to learn how our custom antibody and assay development services can support your next project.
IDT Biologika
IDT Biologika is a global contract development and manufacturing organization for vaccines, cell & gene therapeutics, and fill-finish of other biologics. This includes end-to-end services from process development through drug substance manufacturing up to BSL-2, sterile liquid dosage filling & lyophilization, labeling & packaging to quality control & analytics. We offer clients in B2B business a single source CDMO partner at our sites in the USA and Germany, with seamless end-to-end solutions and the ability to nimbly scale projects from development through to commercialization. IDT Biologika handles every step in manufacturing and packaging of small clinical batches and large-scale commercial products. Our fully integrated services are underscored by our commitment to quality and operational excellence that flows through our best-in-class process and cGMP manufacturing capabilities meeting FDA, EMA and ANVISA standards. If you chose IDT Biologika, you receive reliable high quality services on products because we have the quality and supply mindset underlining the customer needs for speed to market. We supply our client’s products in vials, pre-filled syringes, autoinjectors or as combination products. IDT Biologika is unique in its ability to accommodate the development, testing and manufacture of products for the world’s leading biopharmaceutical companies. Many human vaccines developed by IDT Biologika, together with international partners, are already in use, fighting infectious diseases such as COVID-19, tuberculosis, AIDS, malaria, dengue, ebola and chikungunya. For more information see www.idt-biologika.com. | IDT Biologika is a leading CDMO providing end-to-end services in development and manufacturing of Viral Vaccines, CGT products and aseptic fill-finish for other Biologics and Sterile Injectables. We have GMP sites located in Germany and Maryland, US for clinical and commercial manufacturing. Our excellent track record is manifested by successful inspections and approvals from major regulatory agencies including FDA, EMA and ANVISA and by delivering for commercial programs for over three decades. | IDT Biologika is a global CDMO specializing in biologics, biosimilars and sterile injectables, including vaccines and gene and immune therapeutics. With decades of experience across various manufacturing platforms, we combine cutting-edge innovations in advanced therapies, our manufacturing expertise and our skilled team to deliver customized solutions to our customers. Our end-to-end services include process development, drug substance manufacturing, sterile dosage filling, labeling, packaging and quality control. All analytical services are performed in-house. From early-stage development to clinical and commercial manufacturing, we ensure seamless integration at every step, delivering flexibility, regulatory compliance, and the highest quality standards. Our commitment to operational excellence is reflected in our best-in-class process and GMP manufacturing, meeting FDA, EMA and ANVISA standards. Driven by passion, innovation, and a commitment to excellence, we strive to make a meaningful impact on global healthcare by helping our customers bring their products to market. www.idt-biologika.com
Icosagen
Icosagen is a private, independent family-business, advancing therapeutic proteins from mammalian cells since 26 years. As CRDMO, we uniquely combine pre-clinical CRO & clinical CDMO capabilities at one site, advancing molecules from discovery through R&D stages, into stable IcoCell® CHO cell lines & GMP manufacturing. From mAbs, complex multi-specifics to ADCs or recombinant proteins, We accelerate the programs of over 100 biotechs annually, eliminating error-prone tech transfers to save our partners’ time, cost & effort. Icosagen’s unique business model has enabled the sustainable establishment of drug development initiatives using the established proprietary technologies. Recent patent applications extend to novel drug candidates, including neutralizing and inhibiting antibodies targeting cancer, chronic pain and infectious disease. Icosagen also leads a consortium implementing CAR-T cell therapy in Estonia. | Mammalian Protein Contract Research, Development & Manufacturing Organization (CRDMO). Uniquely combining CRO & CDMO capabilities to discover, develop & manufacture protein drug candidates, from research to pre-clinical to clinical development stages. | With over 25 years of experience, we uniquely combine pre-clinical CRO and clinical CDMO capabilities under one roof. We discover, develop and manufacture protein drug candidates from research concepts up to clinical GMP manufacturing. In 2024 we worked together with over 100 pharmaceutical companies, successfully completing over 450 projects, and producing over 2100 different proteins. Clients come back to us, because of our devotion to meet their satisfaction with our high-quality services and fast communication. They trust us for custom-tailored solutions in every stage of drug development.
HitGen
HitGen Inc. (SSE: 688222.SH), founded in 2012, is headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen is committed to building a world-class innovative biopharmaceutical enterprise and contributing to the better life and health of mankind. Engaged in the discovery and optimization of small molecules and nucleic acid drugs, HitGen dedicates itself to cultivating an internationally leading drug discovery and optimization system centered on four key technology platforms, including DNA-encoded library technology (including DEL design, synthesis and screening, and application expansion), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). It provides new molecular entities (NMEs) at different stages of research and development for the pharmaceutical industry, through its diversified business models including research and development services, out-licensing of projects at different R&D stages, and new drug launches in the long term, with an aim to address unmet clinical needs with innovative therapeutic solutions. As a leader in the field of DEL technology, HitGen has been committed to the development, application and improvement of DEL technology since its establishment. By June 30, 2022, HitGen’s DELs contains more than 1.2 trillion novel, diverse, drug-like small molecules and macrocyclic compounds. These compounds are members of DELs synthesized from many thousands of distinct chemical scaffolds, designed with tractable chemistry, and have yielded proven results for the discovery of small molecule leads against precedented and unprecedented classes of biological targets. Through systematic DEL compound design, HitGen DELs has involved the use of more than 6000 different types of chemical scaffolds, which includes most of the core scaffolds of currently approved small-molecule drugs and many privileged scaffolds of small-molecules in clinical trials, and the approximately 40,000 different building blocks. HitGen has approximately 20 in-house drug discovery projects at different stages of research and development, among which 4 have obtained IND approvals and entered into clinical trials. HitGen is in collaboration with pharmaceutical, biotech and chemical companies, foundations and research institutes in the Americas, Asia, Europe, Africa, and Oceania. For more information, please call +86-28-85197385, +1-508-840-9646 or visit www.hitgen.com. For business development: bd@hitgen.com | HitGen Inc. (SSE: 688222.SH), is a drug discovery research company with headquarters in Chengdu, China, and subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for synthetic therapeutic oligonucleotide technology (STO), and targeted protein degradation technology (TPD). Through our diverse and flexible business models, we have built up collaboration partnership with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage. | About HitGen Inc. HitGen Inc. (SSE: 688222.SH), is a drug discovery research company headquartered in Chengdu, China, with subsidiaries in Cambridge, UK and Houston, USA. HitGen has established leading technology platforms to enable the discovery and optimization of small molecules and nucleic acid-based drugs. Our key technology platforms include world-leading DNA-encoded library technology (DEL), fragment-based drug discovery and structure-based drug design technologies (FBDD/SBDD), as well as the emerging technology platforms for oligonucleotide-based therapeutics (OBT), and targeted protein degradation technology (TPD). Meanwhile, we are developing a DEL+AI+ Automated DMTA (Design-Make-Test-Analyze) molecular optimization platform to accelerate the discovery and optimization process of preclinical candidate compounds. Through our diverse and flexible business models, we have built up collaboration partnerships with several hundred biopharmaceutical research organizations worldwide. HitGen has multiple programmes from early discovery to clinical trial stage.
HiComp
Established in 2014, HiComp Microtech stands as a premier original design manufacturer specializing in advanced microfluidics products and laboratory consumables. Our solutions boost precision, efficiency, and reliability from prototyping to mass production. Quality, performance and affordability are our priorities. | Established in 2014, HiComp Microtech is a leading original design manufacturer (ODM) specializing in advanced microfluidic products and laboratory consumables. Our ISO-certified and FDA-registered facilities span 100,000 sq. ft., including approximately 40,000 sq. ft. of high-standard cleanroom space. We provide precision, efficiency, and reliability from prototyping through volume production, serving renowned pharmaceutical and clinical diagnostic companies globally. With a proven track record, HiComp has successfully completed over 100 commercialized projects. Our services include: • Product Design • 3D Printing • CNC Micro Milling • MEMS Manufacturing • PDMS Manufacturing • Organoids/Organ on a Chip • Cleanroom Injection Molding • Surface Functionalization • Bonding & Sealing • Custom Microwell Plates • Assembly & Automation • Reagent Storage and Lyophilization
Health Enterprises Network
The Health Enterprises Network (HEN) is the region’s premier health care business network, an initiative of Greater Louisville Inc. Formed by area leaders in 2000, HEN’s mission is to champion and foster the growth of the Greater Louisville Region’s health care economy. Comprised of 1200 professionals from 160 investor companies, HEN represents a diverse and growing industry, from hospitals and health services companies to medical device manufacturers and leading health law firms. HEN drives economic growth in the region’s healthcare sector by developing targeted programs and initiatives. As an investor-led organization, HEN brings together thought leaders to deliver meaningful and measurable results through the following strategies: Educational Programming, Communication & Collaboration, BIO International Convention, Professional Networking, and Access to Advocacy.